{
  "meta": {
    "title": "Pulmonary_Hypertension",
    "url": "https://brainandscalpel.vercel.app/pulmonary-hypertension-06517ed3.html",
    "scrapedAt": "2025-11-29T18:25:15.372Z"
  },
  "questions": [
    {
      "id": 20162,
      "choices": [
        {
          "id": 80609,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MRI angiogram of the thorax </span></span></span></p>"
        },
        {
          "id": 80610,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT pulmonary angiogram (CTPA) </span></span></span></p>"
        },
        {
          "id": 80611,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography </span></span></span></p>"
        },
        {
          "id": 80612,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start prostacyclin therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old banker with a history of DVT presents with progressive dyspnea, chest tightness, and syncope. PFTs are normal, but DLCO is reduced. ECHO shows elevated Right Ventricular Systolic Pressure (RVSP). What is the next BEST step?</span></span></p>",
      "unique_key": "Q7968353",
      "question_audio": null,
      "question_video": null,
      "map_id": 20107,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans. B)</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>CT pulmonary angiogram</strong> <strong>CTPA</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The history, symptoms, and elevated RVSP raise strong suspicion for <strong>chronic thromboembolic pulmonary hypertension (CTEPH).</strong> CTPA is the primary imaging modality to identify chronic thromboembolic obstructions in pulmonary arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. MRI angiogram of the thorax:</span></strong><span style=\"font-size:12.0pt\"> While useful for some vascular imaging, not as sensitive or readily available as CTPA for CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Coronary angiography:</span></strong><span style=\"font-size:12.0pt\"> This assesses coronary arteries, not pulmonary circulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Start prostacyclin therapy:</span></strong><span style=\"font-size:12.0pt\"> This is a treatment option for PAH, but not the initial step in diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CTPA is the primary imaging modality for diagnosing chronic thromboembolic pulmonary hypertension (CTEPH).</span></span></span></p>",
      "correct_choice_id": 80610,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20163,
      "choices": [
        {
          "id": 80613,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Riociguat </span></span></span></p>"
        },
        {
          "id": 80614,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sildenafil </span></span></span></p>"
        },
        {
          "id": 80615,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macitentan </span></span></span></p>"
        },
        {
          "id": 80616,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epoprostenol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with a history of pulmonary embolism (PE) has undergone pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH) but continues to experience exertional dyspnea and fatigue. Which of the following is an approved medication for treatment of CTEPH?</span></span></span></p>",
      "unique_key": "Q7162526",
      "question_audio": null,
      "question_video": null,
      "map_id": 20108,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Riociguat</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Riociguat is a soluble guanylate cyclase stimulator specifically approved for the treatment of persistent/recurrent CTEPH after pulmonary endarterectomy, improving exercise capacity and hemodynamics.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sildenafil:</span></strong><span style=\"font-size:12.0pt\"> Primarily used in pulmonary arterial hypertension (PAH), not CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Macitentan:</span></strong><span style=\"font-size:12.0pt\"> An endothelin receptor antagonist, not specifically indicated for CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Espoprostenol:</span></strong><span style=\"font-size:12.0pt\"> </span><span style=\"font-size:12.0pt\">Espoprostenol is a PGI2 analog used in PAAH but not approved for CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Riociguat is an approved medication for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary endarterectomy.</span></strong></span></span></p>",
      "correct_choice_id": 80613,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20164,
      "choices": [
        {
          "id": 80617,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brain Natriuretic Peptide (BNP) levels </span></span></span></p>"
        },
        {
          "id": 80618,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WHO functional class </span></span></span></p>"
        },
        {
          "id": 80619,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mean pulmonary artery pressure (mPAP) </span></span></span></p>"
        },
        {
          "id": 80620,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac index (CI)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman with idiopathic pulmonary arterial hypertension (PAH) is being evaluated for disease progression. Which hemodynamic parameter is the LEAST reliable predictor of survival in PAH patients?</span></span></p>",
      "unique_key": "Q3780879",
      "question_audio": null,
      "question_video": null,
      "map_id": 20109,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Mean pulmonary artery pressure (mPAP)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While mean pulmonary artery pressure (mPAP) is important for the diagnosis and monitoring of PAH, it is not the most reliable predictor of survival. Other parameters such as cardiac index (CI), WHO functional class, and BNP levels are more closely associated with patient outcomes and survival rates in PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Poor prognostic markers in PAH: Features of RVF (ex., </span>&nbsp;<span style=\"font-size:12.0pt\">&nbsp;RAP), WHO class IV, 6MWT &lt; 300m, VO2max &lt; 10.4 mL/kg/min, CI &lt; 2L/min/m2, &uarr; BNP, &uarr; PVR</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Brain Natriuretic Peptide (BNP) levels</span></strong><span style=\"font-size:12.0pt\">: Elevated BNP levels correlate with right ventricular dysfunction and are a strong predictor of morbidity and mortality in PAH patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. WHO functional class</span></strong><span style=\"font-size:12.0pt\">: The functional classification of patients based on symptoms and exercise capacity is a well-established predictor of survival in PAH.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cardiac index (CI)</span></strong><span style=\"font-size:12.0pt\">: A measure of cardiac output relative to body size, CI is a critical parameter in assessing the severity and prognosis of PAH. A lower CI is associated with worse outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mean pulmonary artery pressure (mPAP) is not the most reliable predictor of survival in PAH compared to parameters such as cardiac index (CI), WHO functional class, and BNP levels.</span></span></span></p>",
      "correct_choice_id": 80619,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20165,
      "choices": [
        {
          "id": 80621,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;15 mmHg </span></span></span></p>"
        },
        {
          "id": 80622,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;20 mmHg </span></span></span></p>"
        },
        {
          "id": 80623,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;25 mmHg </span></span></span></p>"
        },
        {
          "id": 80624,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;30 mmHg</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 48-year-old man with systemic sclerosis undergoes right heart catheterization. What is the threshold value of mean pulmonary arterial pressure (mPAP) that confirms the diagnosis of pulmonary hypertension (PH)?</span></span></span></p>",
      "unique_key": "Q8149968",
      "question_audio": null,
      "question_video": null,
      "map_id": 20110,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) &gt;20 mmHg</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PH is defined as mPAP &gt; 20 mmHg at rest. Values above this threshold indicate increased pressure in the pulmonary circulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. &gt;15 mmHg:</span></strong><span style=\"font-size:12.0pt\"> Current cut off is &gt; 20 mm Hg for diagnosing PH</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. &gt;25 mmHg:</span></strong><span style=\"font-size:12.0pt\"> Old recommendation, not followed now.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. &gt;30 mmHg:</span></strong><span style=\"font-size:12.0pt\"> False</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary hypertension is defined as mPAP &gt; 20 mmHg at rest</span></span></p>",
      "correct_choice_id": 80622,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20166,
      "choices": [
        {
          "id": 80625,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 </span></span></span></p>"
        },
        {
          "id": 80626,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CFTR </span></span></span></p>"
        },
        {
          "id": 80627,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BMPR2 </span></span></span></p>"
        },
        {
          "id": 80628,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">KCNH2</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman with a family history of early-onset pulmonary hypertension presents with exertional dyspnea. Genetic testing is being considered. Which gene is most commonly associated with hereditary pulmonary arterial hypertension?</span></span></p>",
      "unique_key": "Q2722021",
      "question_audio": null,
      "question_video": null,
      "map_id": 20111,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) BMPR2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the BMPR2 gene are the most frequent cause of hereditary PAH, leading to dysregulation of pulmonary vascular growth and remodeling.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BRCA1:</span></strong><span style=\"font-size:12.0pt\"> Associated with breast and ovarian cancer susceptibility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CFTR:</span></strong><span style=\"font-size:12.0pt\"> Associated with cystic fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. KCNH2:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Associated with long QT syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the BMPR2 gene are the most frequent cause of hereditary pulmonary arterial hypertension (PAH), leading to dysregulation of pulmonary vascular growth and remodeling.</span></span></span></p>",
      "correct_choice_id": 80627,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20167,
      "choices": [
        {
          "id": 80629,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial Pulmonary artery hypertension (FPAH)</span></span></span></p>"
        },
        {
          "id": 80630,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic thromboembolic pulmonary hypertension (CTEPH)</span></span></span></p>"
        },
        {
          "id": 80631,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary arterial hypertension (IPAH) </span></span></span></p>"
        },
        {
          "id": 80632,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Associated Pulmonary artery hypertension (APAH)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old woman presents with progressive dyspnea. Initial CXR, CT, and PFT are normal. However, echocardiography reveals an elevated RVSP of 55 mmHg. Right heart catheterization reveals normal PCWP and mPAP of 35 mmHg. What is the most likely cause of her dyspnea?</span></span></p>",
      "unique_key": "Q5624830",
      "question_audio": null,
      "question_video": null,
      "map_id": 20112,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C)&nbsp;Idiopathic pulmonary arterial hypertension (IPAH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary arterial hypertension (IPAH) is diagnosed in the absence of known familial, associated, or secondary causes of PAH. The findings of elevated RVSP, normal PCWP, and elevated mPAP (&ge; 25 mmHg) on right heart catheterization are consistent with PAH. Given the normal initial imaging and PFTs, IPAH is the most likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Familial Pulmonary artery hypertension (FPAH):</span></strong><span style=\"font-size:12.0pt\"> While this is a possible cause, there is no indication of a family history provided in the case, making it less likely compared to IPAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chronic thromboembolic pulmonary hypertension (CTEPH):</span></strong><span style=\"font-size:12.0pt\"> Typically, patients have a history of thromboembolic events, and CT may show chronic thromboembolic disease. The normal CT in this case makes CTEPH less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Associated Pulmonary artery hypertension (APAH):</span></strong><span style=\"font-size:12.0pt\"> This refers to PAH associated with other conditions (e.g., connective tissue disease, HIV, portal hypertension). There is no mention of such associated conditions in the patient&#39;s history, making IPAH more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic pulmonary arterial hypertension (IPAH) is diagnosed in the absence of known familial, associated, or secondary causes of PAH, and is characterized by elevated RVSP, normal PCWP, and elevated mPAP (&ge; 25 mmHg).</span></span></p>",
      "correct_choice_id": 80631,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20168,
      "choices": [
        {
          "id": 80633,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Group 1</span></span></span></p>"
        },
        {
          "id": 80634,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Group 2</span></span></span></p>"
        },
        {
          "id": 80635,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Group 3</span></span></span></p>"
        },
        {
          "id": 80636,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Group 4</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old smoker with progressive breathlessness for one year presents with hyperinflated lungs on chest X-ray and moderate airflow obstruction on PFTs. Echocardiogram reveals an RVSP of 60 mmHg. According to the WHO classification, which group of pulmonary hypertension (PH) does this patient most likely belong to?</span></span></p>",
      "unique_key": "Q1445748",
      "question_audio": null,
      "question_video": null,
      "map_id": 20113,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Group 3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s history of smoking, hyperinflated lungs on X-ray, and obstructive PFTs point towards an underlying lung disease (COPD), which is a common cause of Group 3 PH (PH due to Lung Diseases and/or Hypoxemia)1`</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Group 1: PAH -&nbsp;</span></strong><span style=\"font-size:12.0pt\">Typically occurs in younger individuals without significant lung disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Group 2:</span></strong><span style=\"font-size:12.0pt\"> Would be caused by left heart disease, not supported by the clinical picture.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Group 4: CTEPH -&nbsp;</span></strong><span style=\"font-size:12.0pt\">While possible in smokers, the absence of a prior PE history makes this less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s history of smoking, hyperinflated lungs on X-ray, and obstructive PFTs point towards an underlying lung disease (COPD), which is a common cause of Group 3 PH (PH due to Lung Diseases and/or Hypoxemia).</span></span></span></p>",
      "correct_choice_id": 80635,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20169,
      "choices": [
        {
          "id": 80637,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-capillary pulmonary hypertension </span></span></span></p>"
        },
        {
          "id": 80638,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Post-capillary pulmonary hypertension </span></span></span></p>"
        },
        {
          "id": 80639,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Combined post- and pre-capillary pulmonary hypertension</span></span></span></p>"
        },
        {
          "id": 80640,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary arterial hypertension (IPAH)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient undergoes right heart catheterization (RHC) for evaluation of pulmonary hypertension. The results show:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP: 50 mmHg</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PCWP: 40 mmHg</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PVR: 2 Wood units</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the likely type of pulmonary hypertension this patient is suffering from?</span></span></span></p>",
      "unique_key": "Q5371019",
      "question_audio": null,
      "question_video": null,
      "map_id": 20114,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Post-capillary pulmonary hypertension</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The elevated mPAP and PCWP (which reflects left atrial pressure) with normal PVR are characteristic of post-capillary pulmonary hypertension, often caused by left heart disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><strong><span style=\"font-size:12.0pt\">. Pre-capillary pulmonary hypertension</span></strong><strong><span style=\"font-size:12.0pt\">:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Would show elevated PVR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span style=\"font-size:12pt\">Combined post- and pre-capillary pulmonary hypertension:</span><span style=\"font-size:14.6667px\">&nbsp;</span></strong><span style=\"font-size:12pt\">Would show elevated mPAP, PCWP, and PVR.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><strong><span style=\"font-size:12pt\">Idiopathic pulmonary arterial hypertension (IPAH):</span><span style=\"font-size:14.6667px\">&nbsp;</span></strong><span style=\"font-size:12pt\">A type of pre-capillary PH, would have elevated PVR.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The elevated mPAP and PCWP (which reflects left atrial pressure) with normal PVR are characteristic of post-capillary pulmonary hypertension, often caused by left heart disease.</span></span></span></p>",
      "correct_choice_id": 80638,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20170,
      "choices": [
        {
          "id": 80641,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nifedipine </span></span></span></p>"
        },
        {
          "id": 80642,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ambrisentan </span></span></span></p>"
        },
        {
          "id": 80643,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epoprostenol </span></span></span></p>"
        },
        {
          "id": 80644,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tadalafil</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old woman with Pulmonary arterial hypertension (PAH) undergoes a vasoreactivity test during right heart catheterization. The test is positive, showing a significant decrease in mPAP with vasodilators. Which medication would be the most appropriate initial treatment for this patient?</span></span></p>",
      "unique_key": "Q2899499",
      "question_audio": null,
      "question_video": null,
      "map_id": 20115,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Nifedipine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive vasoreactivity testing suggests that the patient&#39;s pulmonary vasculature is responsive to vasodilators. High-dose calcium channel blockers (CCBs) like nifedipine are the first-line therapy for vasoreactive PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ambrisentan:</span></strong><span style=\"font-size:12.0pt\"> Endothelin receptor antagonist, used in non-vasoreactive PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Epoprostenol:</span></strong><span style=\"font-size:12.0pt\"> Prostacyclin analog, used in severe PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tadalafil:</span></strong><span style=\"font-size:12.0pt\"> PDE5 inhibitor, used in non-vasoreactive PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Positive vasoreactivity testing suggests that the patient&#39;s pulmonary vasculature is responsive to vasodilators. High-dose calcium channel blockers (CCBs) like nifedipine are the first-line therapy for vasoreactive PAH.</span></span></p>",
      "correct_choice_id": 80641,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20171,
      "choices": [
        {
          "id": 80645,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sotatercept </span></span></span></p>"
        },
        {
          "id": 80646,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Luspatercept </span></span></span></p>"
        },
        {
          "id": 80647,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Selexipag</span></span></span></p>"
        },
        {
          "id": 80648,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macitentan</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with pulmonary arterial hypertension (PAH) is being considered for a novel therapy that targets the activin signaling pathway to reduce pulmonary vascular remodeling. Which medication is an activin receptor fusion protein that has been shown to improve cardiopulmonary function in PAH?</span></span></span></p>",
      "unique_key": "Q2472379",
      "question_audio": null,
      "question_video": null,
      "map_id": 20116,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Sotatercept</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sotatercept is an activin receptor type IIA fusion protein that binds and inhibits members of the TGF-&beta; superfamily, including activins, leading to improved hemodynamics and exercise capacity in PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Luspatercept:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Activin receptor type IIB fusion protein that binds and inhibits members of the TGF-&beta; superfamily. This reduces SMAD signalling and increases erythroid maturation. Used to treat anemia in MDS and thalassemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Selexipag:</span></strong><span style=\"font-size:12.0pt\"> Prostacyclin receptor agonist used in PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Macitentan:</span></strong><span style=\"font-size:12.0pt\"> Endothelin receptor antagonist used in PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sotatercept is an activin receptor type IIA fusion protein that binds and inhibits members of the TGF-&beta; superfamily, including activins, leading to improved hemodynamics and exercise capacity in PAH.</span></span></span></p>",
      "correct_choice_id": 80645,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20172,
      "choices": [
        {
          "id": 80649,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long-term anticoagulation </span></span></span></p>"
        },
        {
          "id": 80650,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary endarterectomy </span></span></span></p>"
        },
        {
          "id": 80651,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Balloon pulmonary angioplasty </span></span></span></p>"
        },
        {
          "id": 80652,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung transplantation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old female presents with progressive dyspnea and exercise intolerance. She has a history of recurrent pulmonary embolisms. Right heart catheterization confirms pulmonary hypertension, and imaging studies show organized thrombi within the pulmonary arteries. Which of the following is considered the best treatment option for her condition?</span></span></span></p>",
      "unique_key": "Q8377250",
      "question_audio": null,
      "question_video": null,
      "map_id": 20120,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Pulmonary endarterectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary endarterectomy is the best treatment for chronic thromboembolic pulmonary hypertension (CTEPH). It is a surgical procedure that removes organized thrombi from the pulmonary arteries, improving hemodynamics and symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Long-term anticoagulation</span></strong><span style=\"font-size:12.0pt\">: Essential for preventing new clots but does not address the existing organized thrombi causing CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Balloon pulmonary angioplasty</span></strong><span style=\"font-size:12.0pt\">: An option for patients who are not candidates for surgery or have residual disease post-endarterectomy, but not considered the first-line treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lung transplantation</span></strong><span style=\"font-size:12.0pt\">: Considered for patients with advanced disease who are not candidates for other treatments, but pulmonary endarterectomy is preferred if feasible.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary endarterectomy is the best treatment for chronic thromboembolic pulmonary hypertension (CTEPH) as it removes organized thrombi from the pulmonary arteries, improving hemodynamics and symptoms.</span></span></span></p>",
      "correct_choice_id": 80650,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7143,
      "choices": [
        {
          "id": 28540,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diuretics are given to reduce peripheral edema </span></span></span></p>"
        },
        {
          "id": 28541,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxygen supplementation is given if PO2 is reduced </span></span></span></p>"
        },
        {
          "id": 28542,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For patients with persistent right heart failure, lung transplantation may be considered </span></span></span></p>"
        },
        {
          "id": 28543,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary arterial hypertension is more common in males</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old male presents to the OPD with exertional dyspnea, fatigue, syncope, and peripheral edema. On examination, JVP is raised and a loud P2 is noted. ECHO shows right atrial and right ventricular enlargement with a mean pulmonary artery pressure of 30 mmHg. Which of the following statements is false regarding the condition?</span></span></span></p>",
      "unique_key": "Q5913936",
      "question_audio": null,
      "question_video": null,
      "map_id": 20117,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Pulmonary arterial hypertension is more common in males</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic Pulmonary arterial hypertension (IPAH) is actually more common in females than in males. The female-to-male ratio is approximately 3:1 and tend to </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">present in the fourth and fifth decades. Major presenting symptom is dyspnea, which is often insidious. Mean survival of IPAH is 5-6 years, even with therapy. Prognosis is slightly better in males compared to females. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Diuretics are given to reduce peripheral edema</span></strong><span style=\"font-size:12.0pt\">: True. Diuretics are commonly used to manage symptoms of right heart failure, including peripheral edema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oxygen supplementation is given if PO2 is reduced</span></strong><span style=\"font-size:12.0pt\">: True. Oxygen therapy is used to maintain adequate oxygenation and prevent hypoxemia in PAH patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. For patients with persistent right heart failure, lung transplantation may be considered</span></strong><span style=\"font-size:12.0pt\">: True. Lung transplantation is a treatment option for patients with advanced PAH and right heart failure that is refractory to medical therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic Pulmonary arterial hypertension (IPAH) is more common in females than in males, with a female-to-male ratio of approximately 3:1.</span></span></p>",
      "correct_choice_id": 28543,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7144,
      "choices": [
        {
          "id": 28544,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP &gt;20 mm Hg, PCWP &gt; 15 mm Hg </span></span></span></p>"
        },
        {
          "id": 28545,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP &gt;25 mm Hg, PCWP &gt; 15 mm Hg </span></span></span></p>"
        },
        {
          "id": 28546,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP &gt;20 mm Hg, PCWP &lt; 15 mm Hg</span></span></span></p>"
        },
        {
          "id": 28547,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP &gt;25 mm Hg, PCWP &lt; 15 mm Hg</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old male presents with chronic progressive breathlessness. On examination, his JVP is elevated, there is a loud 2nd heart sound, and bilateral pedal edema. Right heart catheterization reveals pulmonary hypertension. Pre-capillary pulmonary hypertension is defined as:</span></span></p>",
      "unique_key": "Q2643322",
      "question_audio": null,
      "question_video": null,
      "map_id": 20118,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) mPAP &gt;20 mm Hg, PCWP &lt; 15 mm Hg</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to updated recommendations, pre-capillary pulmonary hypertension is defined by a mean pulmonary artery pressure (mPAP) greater than 20 mm Hg and a pulmonary capillary wedge pressure (PCWP) less than 15 mm Hg.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. mPAP &gt;20 mm Hg, PCWP &gt; 15 mm Hg</span></strong><span style=\"font-size:12.0pt\">: This describes post-capillary pulmonary hypertension, indicating elevated pressures due to left heart disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. mPAP &gt;25 mm Hg, PCWP &gt; 15 mm Hg</span></strong><span style=\"font-size:12.0pt\">: This was the previous threshold for post-capillary pulmonary hypertension but has been updated to mPAP &gt;20 mm Hg.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. mPAP &gt;25 mm Hg, PCWP &lt; 15 mm Hg</span></strong><span style=\"font-size:12.0pt\">: This was the previous threshold for pre-capillary pulmonary hypertension but has been updated to mPAP &gt;20 mm Hg.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-capillary pulmonary hypertension is defined by a mean pulmonary artery pressure (mPAP) greater than 20 mm Hg and a pulmonary capillary wedge pressure (PCWP) less than 15 mm Hg.</span></span></span></p>",
      "correct_choice_id": 28546,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7166,
      "choices": [
        {
          "id": 28632,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic obstructive pulmonary disease (COPD) </span></span></span></p>"
        },
        {
          "id": 28633,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary arterial hypertension (IPAH) </span></span></span></p>"
        },
        {
          "id": 28634,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Schistosomiasis </span></span></span></p>"
        },
        {
          "id": 28635,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left heart disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male from an endemic region presents with signs of pulmonary hypertension (PH). He has a history of hepatosplenic disease and portal hypertension. Which of the following is the most likely cause of his pulmonary hypertension?</span></span></span></p>",
      "unique_key": "Q1216890",
      "question_audio": null,
      "question_video": null,
      "map_id": 20119,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Schistosomiasis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Globally, schistosomiasis is a common cause of pulmonary hypertension (PH), particularly in individuals with hepatosplenic disease and portal hypertension. The inflammation from the infection triggers maladaptive pulmonary vascular changes. Diagnosis is confirmed by finding the parasite ova in the urine or stool of symptomatic patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic obstructive pulmonary disease (COPD)</span></strong><span style=\"font-size:12.0pt\">: Typically associated with a history of smoking and different clinical features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Idiopathic pulmonary arterial hypertension (IPAH)</span></strong><span style=\"font-size:12.0pt\">: A diagnosis of exclusion when other causes of PH are ruled out.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Left heart disease</span></strong><span style=\"font-size:12.0pt\">: Causes post-capillary pulmonary hypertension, typically with elevated PCWP, which is not the scenario here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-capillary pulmonary hypertension is defined by a mean pulmonary artery pressure (mPAP) greater than 20 mm Hg and a pulmonary capillary wedge pressure (PCWP) less than 15 mm Hg.</span></span></span></p>",
      "correct_choice_id": 28634,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}